Nir Naor was named Chief Financial Officer of Neuronetics, Inc. As of November 6, 2026, Neuronetics, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 6, 2026 to August 17, 2026, naming 2 appointments (Form 8-K, July 20, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Neuronetics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Nir Naor · 8-K, 2026-08-17
- · In / out: In · Person: Nir Naor · Role: Chief Financial Officer · 8-K, 2026-07-20
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-23
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-06
Neuronetics, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-06 to 2026-08-17. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Neuronetics, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-04-06 (layoff filings and notices).
Also on the record for Neuronetics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 24, 2026 | Stake report, Schedule 13D/A, by Chernett Jorey | 13.92% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13D/A, by Chernett Jorey | 15.22% of the class | 5%+ stakes | Source |
| May 27, 2026 | Stake report, Schedule 13D/A, by Chernett Jorey | 15.17% of the class | 5%+ stakes | Source |
| April 8, 2026 | Stake report, Schedule 13D/A, by Chernett Jorey | 14.12% of the class | 5%+ stakes | Source |
| March 31, 2026 | Stake report, Schedule 13D, by Chernett Jorey | 14.12% of the class | 5%+ stakes | Source |
| March 18, 2026 | Stake report, Schedule 13G/A, by Chernett Jorey | 10.85% of the class | 5%+ stakes | Source |
| March 17, 2026 | Stake report, Schedule 13G, by Parian Ultreia LP | 7% of the class | 5%+ stakes | Source |
| March 4, 2026 | Stake report, Schedule 13D/A, by MADRYN ASSET MANAGEMENT, LP | 30.3% of the class | 5%+ stakes | Source |
| February 4, 2026 | Stake report, Schedule 13G/A, by Chernett Jorey | 9.9% of the class | 5%+ stakes | Source |
| November 24, 2025 | Stake report, Schedule 13G, by Chernett Jorey | 6.4% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13D/A, by MADRYN ASSET MANAGEMENT, LP | 31.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Neuronetics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Neuronetics, Inc. and the records around it.
Neuronetics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Apr 2026
- Who owns it
Companies that share a holder
- MADRYN ASSET MANAGEMENT, LP also filed stake reports on 1 other company: Venus Concept Inc. (Mar 2026)
- Parian Ultreia LP also filed stake reports on 2 other companies: EXAGEN INC. (May 2026), Airsculpt Technologies, Inc. (Apr 2026)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), KAZIA THERAPEUTICS LTD (Aug 2026)
Watch Neuronetics, Inc.
Get an email when Neuronetics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Neuronetics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Neuronetics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neuronetics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-17 | In | 8-K, 2026-08-17 | |||
| 2026-07-20 | In | Chief Financial Officer | 8-K, 2026-07-20 | ||
| 2026-06-23 | Reported | not named in the filing | 8-K, 2026-06-23 | ||
| 2026-04-06 | Reported | not named in the filing | 8-K, 2026-04-06 |
Who leads Neuronetics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Nir Naor, appointed (filed 2026-07-20).
New leaders reset buying decisions — get the Full Report on Neuronetics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Neuronetics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Neuronetics, Inc.Every change, in the filing's words
Appointed: Nir Naor
On August 12, 2026, the Board appointed Mr. Naor to serve as the Company's principal financial and accounting officer.
- (b) On August 11, 2026, in connection with Mr. Naor's appointment (as described below), Francis X. Brown III's appointment as Neuronetics, Inc.'s (the "Company") interim principal financial and accounting officer ended.
- Such event is not the result of any dispute or disagreement between Mr. Brown and the Company, the Company's management, or the Company's Board on any matter relating to the Company's operations, policies, or practices.
- Mr. Brown will continue to serve as a consultant.
- (c) As previously disclosed, the Board of Directors of the Company (the "Board") appointed Nir Naor as the Company's Executive Vice President, Chief Financial Officer, and Treasurer with an effective date of July 23, 2026.
- Mr. Naor's title is now Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer.
- Mr. Naor did not receive any new compensation in connection with his appointment as the principal financial and accounting officer, his appointment as the corporate secretary, or the modification of his title.
Appointed: Nir Naor, Chief Financial Officer
(c) On July 9, 2026, the Board appointed Nir Naor as the Company's Executive Vice President, Chief Financial Officer, and Treasurer with an effective date on or about July 23, 2026.
- (b) On July 17, 2026, Neuronetics, Inc. (the "Company") and W. Andrew Macan, who has served as Executive Vice President, Chief Legal Officer, and Corporate Secretary and in various other similar capacities since January 21, 2020, entered into a Separation Agreement (the "Separation Agreement").
- Mr. Macan's Separation Date (as defined in the Separation Agreement) is August 15, 2026.
- On the Separation Date, Mr. Macan will be entitled to his retention bonus in the gross amount of $231,750.00 and the retention award granted to him by the Board of Directors of the Company (the "Board") on December 30, 2025 in the amount of 164,361 Restricted Stock Units, which shall vest on the Separation Date.
- Mr. Macan will also be entitled to a Separation Payment in the amount of $475,087.50, minus taxes and withholdings payable on regularly scheduled payroll dates for a consecutive period of 12 months.
- Mr. Macan's decision to enter into the Separation Agreement is not the result of any dispute or disagreement with the Company, the Company's management, or the Company's Board of Directors on any matter relating to the Company's operations, policies, or practices.
Reported
(c) On June 16, 2026, the board of directors of the Company (the "Board") promoted Cory Anderson from the position of Senior Vice President, Chief Technology Officer to the position of Executive Vice President, General Manager of Greenbrook effective July 1, 2026 (the "Anderson Promotion Date").
- Mr. Anderson previously served as the Company's SVP R&D and Clinical, Chief Technology Officer since January 2025, SVP R&D and Clinical from January 2023 until December 2024, VP R&D and Clinical from January 2022 until December 2022 and VP Clinical Affairs and Medical Operations, Interim VP R&D from March 2021 until December 2021.
- Prior to joining the Company, Mr. Anderson served as Vice President, Business Development and Marketing at Sebacia.
- During his time at Sebacia, he led phase IV clinical trials in five countries and strategically guided the company's R&D pipeline.
- Prior to Sebacia, he was VP Business Development at The Innovation Factory ("TIF") and a Principal at Accuitive Medical Ventures ("AMV").
- During his time at TIF and AMV, Mr. Anderson managed operations of two portfolio companies in the ophthalmic space, evaluated new business and investment opportunities, and supported investments in the portfolio of companies.
- Prior to his time at TIF and AMV, Mr. Anderson held positions of increasing responsibility within Product Development and Marketing at Novoste Corporation where he developed products for interventional cardiology.
- Mr. Anderson has been a board observer and investor in two successful exits of venture-backed companies: AqueSys (acquired by Allergan/AbbVie, NYSE: ABBV) and MyoScience (acquired by Pacira BioSciences, NASDAQ: PCRX).
Reported
Mr. Pfanstiel's decision to resign is not the result of any dispute or disagreement with the Company, the Company's management, or the Company's Board of Directors on any matter relating to the Company's operations, policies, or practices.
- On March 31, 2026, Steven E. Pfanstiel, who has served as Executive Vice President, Chief Financial Officer, and Treasurer since July 15, 2025, informed the Company of his intention to resign on May 1, 2026.
- The Company has commenced a search for Mr. Pfanstiel's successor.
Tools for this story
Each opens in a new tab, filled in for Neuronetics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.